Cite
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome.
MLA
Roerden, Malte, et al. “Expression Levels of HLA-DR in Acute Myeloid Leukemia: Implications for Antigenicity and Clinical Outcome.” Leukemia & Lymphoma, vol. 62, no. 8, Aug. 2021, pp. 1907–19. EBSCOhost, https://doi.org/10.1080/10428194.2021.1885659.
APA
Roerden, M., Märklin, M., Salih, H. R., Bethge, W. A., Klein, R., Rammensee, H.-G., Nelde, A., & Walz, J. S. (2021). Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcome. Leukemia & Lymphoma, 62(8), 1907–1919. https://doi.org/10.1080/10428194.2021.1885659
Chicago
Roerden, Malte, Melanie Märklin, Helmut R. Salih, Wolfgang A. Bethge, Reinhild Klein, Hans-Georg Rammensee, Annika Nelde, and Juliane S. Walz. 2021. “Expression Levels of HLA-DR in Acute Myeloid Leukemia: Implications for Antigenicity and Clinical Outcome.” Leukemia & Lymphoma 62 (8): 1907–19. doi:10.1080/10428194.2021.1885659.